DK173589B1 - Anvendelse af D-cycloserin og dets forstadier eller farmaceutisk acceptable salte deraf til fremstilling af præparater til - Google Patents

Anvendelse af D-cycloserin og dets forstadier eller farmaceutisk acceptable salte deraf til fremstilling af præparater til Download PDF

Info

Publication number
DK173589B1
DK173589B1 DK198806690A DK669088A DK173589B1 DK 173589 B1 DK173589 B1 DK 173589B1 DK 198806690 A DK198806690 A DK 198806690A DK 669088 A DK669088 A DK 669088A DK 173589 B1 DK173589 B1 DK 173589B1
Authority
DK
Denmark
Prior art keywords
alkyl
atoms
hydrido
dosage form
pharmaceutically acceptable
Prior art date
Application number
DK198806690A
Other languages
Danish (da)
English (en)
Other versions
DK669088A (da
DK669088D0 (da
Inventor
Alex A Cordi
Gail E Handelmann
Joseph B Monahan
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of DK669088D0 publication Critical patent/DK669088D0/da
Publication of DK669088A publication Critical patent/DK669088A/da
Application granted granted Critical
Publication of DK173589B1 publication Critical patent/DK173589B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK198806690A 1987-12-01 1988-11-30 Anvendelse af D-cycloserin og dets forstadier eller farmaceutisk acceptable salte deraf til fremstilling af præparater til DK173589B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers
US12712187 1987-12-01

Publications (3)

Publication Number Publication Date
DK669088D0 DK669088D0 (da) 1988-11-30
DK669088A DK669088A (da) 1989-06-02
DK173589B1 true DK173589B1 (da) 2001-04-02

Family

ID=22428413

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198806690A DK173589B1 (da) 1987-12-01 1988-11-30 Anvendelse af D-cycloserin og dets forstadier eller farmaceutisk acceptable salte deraf til fremstilling af præparater til

Country Status (20)

Country Link
US (1) US4904681A (fr)
EP (2) EP0319824B1 (fr)
JP (2) JPH0621065B2 (fr)
KR (1) KR0134198B1 (fr)
AT (1) ATE68698T1 (fr)
AU (4) AU622630B2 (fr)
CA (1) CA1328617C (fr)
DE (1) DE3865817D1 (fr)
DK (1) DK173589B1 (fr)
ES (1) ES2040314T3 (fr)
FI (1) FI885559A0 (fr)
GR (1) GR3003571T3 (fr)
IE (1) IE61825B1 (fr)
IL (1) IL88531A (fr)
NO (1) NO885337D0 (fr)
NZ (1) NZ227131A (fr)
PH (1) PH26467A (fr)
PT (1) PT89109B (fr)
WO (1) WO1989005144A1 (fr)
ZA (1) ZA888981B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
WO1996015787A1 (fr) * 1994-11-23 1996-05-30 G.D. Searle & Co. Utilisation de composes amino-isoxazolidone pour le traitement de troubles de la memoire consecutives a des lesions traumatiques du cerveau
WO1996015788A1 (fr) * 1994-11-23 1996-05-30 G.D. Searle & Co. Emploi de composes d'amino-isoxazolidone pour ameliorer la memoire implicite
CA2216648A1 (fr) * 1995-02-15 1996-08-22 Bearsden Bio, Inc. Modulateurs a base d'aminoacides alkylcarboxy du recepteur de kanaite
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
WO1997020553A1 (fr) * 1995-12-07 1997-06-12 Javitt Daniel C Traitement des symptomes negatifs et cognitifs de la schizophrenie par des antagonistes de l'assimilation de la glycine
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
RU2219924C2 (ru) 1998-04-14 2003-12-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения нейропсихиатрических расстройств
ES2262322T3 (es) * 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
KR20040016849A (ko) * 2001-04-02 2004-02-25 파노라마 리서치, 인크. 치료제로 사용되는 항산화제 니트로옥사이드 및 니트론류
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
EP1660634A4 (fr) * 2003-08-08 2009-02-18 Burnham Inst Regulation des recepteurs de nmda mediee par la proteine p16
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2604052C (fr) * 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methode et compositions de traitement des affections du snc
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG10201811584RA (en) 2010-02-11 2019-01-30 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
DK2951183T3 (da) 2013-01-29 2019-06-03 Aptinyx Inc Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf
BR112015018094A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
EA032153B1 (ru) 2013-01-29 2019-04-30 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
CA2899010A1 (fr) 2013-01-29 2014-08-07 Naurex, Inc. Modulateurs spirolactames d'un recepteur nmda et leurs utilisations
WO2017201285A1 (fr) 2016-05-19 2017-11-23 Aptinyx Inc. Modulateurs spirolactames des récepteurs nmda et leurs utilisations
MX2018014202A (es) 2016-05-19 2019-06-20 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
CN109843889B (zh) 2016-08-01 2022-03-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda调节剂和使用其的方法
AU2017306136B2 (en) 2016-08-01 2021-10-21 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CN109937204B (zh) 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
PE20190502A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
EP3427729A1 (fr) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probénécide destiné à être utilisé dans le traitement de maladies, troubles ou états épileptiques
AU2019215058A1 (en) 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3050800C2 (fr) * 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be

Also Published As

Publication number Publication date
IE61825B1 (en) 1994-11-30
US4904681A (en) 1990-02-27
DK669088A (da) 1989-06-02
EP0319824B1 (fr) 1991-10-23
IL88531A (en) 1993-02-21
CA1328617C (fr) 1994-04-19
AU622630B2 (en) 1992-04-16
ES2040314T3 (es) 1995-04-01
FI885559A0 (fi) 1988-11-30
KR890009392A (ko) 1989-08-01
IL88531A0 (en) 1989-06-30
EP0421997A1 (fr) 1991-04-17
JPH05201859A (ja) 1993-08-10
ZA888981B (en) 1990-01-31
EP0319824A1 (fr) 1989-06-14
ATE68698T1 (de) 1991-11-15
NZ227131A (en) 1991-09-25
JPH0621065B2 (ja) 1994-03-23
PH26467A (en) 1992-07-27
KR0134198B1 (ko) 1998-04-21
PT89109B (pt) 1993-07-30
IE883567L (en) 1989-06-01
NO885337D0 (no) 1988-11-30
AU2813089A (en) 1989-07-05
AU1083992A (en) 1992-05-07
JPH01193220A (ja) 1989-08-03
DK669088D0 (da) 1988-11-30
WO1989005144A1 (fr) 1989-06-15
PT89109A (pt) 1989-12-29
GR3003571T3 (fr) 1993-03-16
AU2631988A (en) 1989-06-01
DE3865817D1 (fr) 1991-11-28
AU7746794A (en) 1995-01-05

Similar Documents

Publication Publication Date Title
DK173589B1 (da) Anvendelse af D-cycloserin og dets forstadier eller farmaceutisk acceptable salte deraf til fremstilling af præparater til
RU2566821C2 (ru) Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение
US8822462B2 (en) Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
RU2384574C2 (ru) БЕНЗО[d] ИЗОКСАЗОЛ-3-ОЛЬНЫЕ ИНГИБИТОРЫ DAAO
EA031746B1 (ru) СТИМУЛЯТОРЫ sGC
US4874780A (en) Anticancer compounds
CA2007332C (fr) Utilisation d'un agoniste partiel de la glycine b comme neuroleptique
JP2004535398A (ja) ＮＡＡＬＡＤａｓｅ阻害剤としてのヒドロキサム酸およびアシルヒドロキサミン
SU1545941A3 (ru) Способ получени оксотиазолидиновых соединений
WO2017131097A1 (fr) Dérivé d'adamantane et son utilisation
US5087633A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5468763A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US20040019200A1 (en) Mixed steroidal 1, 2, 4, 5- tetraoxane compounds and methods of making and using thereof
US5476867A (en) Pharmaceutical compositions
US20010027204A1 (en) Use of amino-isoxazolidone compounds for improvement of implicit memory
WO2018181986A1 (fr) Dérivé d'adamantylméthylamine et son utilisation en tant que produit pharmaceutique
US20190194227A1 (en) Bmp potentiators
EA045493B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
JPH01287023A (ja) 利尿剤

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK